Page last updated: 2024-09-24

4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl

Description

4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID105101
CHEMBL ID311000
CHEBI ID34220
SCHEMBL ID2279047
MeSH IDM0389845

Synonyms (26)

Synonym
BIDD:ER0191
CHEMBL311000 ,
chebi:34220 ,
4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl
(1,1'-biphenyl)-4-ol, 2',3',4',5'-tetrachloro-
4'-hydroxy-2,3,4,5-tetrachlorobiphenyl
2,3,4,5-tetrachloro-4'-biphenylol
67651-34-7
[1,1'-biphenyl]-4-ol, 2',3',4',5'-tetrachloro-
[1,1'-biphenyl]-4-ol, 2',3',4',5'-tetrachloro- (9ci)
4-hydroxy-2',3',4',5'-tetrachlorobiphenyl
2',3',4',5'-tetrachloro-4-biphenylol
2',3',4',5'-tetrachloro-(1,1'-biphenyl)-4-ol
2',3',4',5'-tetrachlorobiphenyl-4-ol
oh-pcb-61
ccris 9184
4-(2,3,4,5-tetrachlorophenyl)phenol
bdbm50410496
unii-lh750s39fx
lh750s39fx ,
SCHEMBL2279047
DTXSID5022350
AKOS032948983
Q27115915
2',3',4',5'-tetrachloro-4-biphenylol (oh-pcb-61)
PD015520

Drug Classes (2)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
tetrachlorobenzeneAny member of the class of chlorobenzenes carrying four chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)16.21810.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID161430Displacement of [125I]thyroxin from human plasma prealbumin.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID161431Thyroxine binding constant on human plasma prealbumin.1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID230635KPCB/ K352 ratio of the compound1986Journal of medicinal chemistry, Dec, Volume: 29, Issue:12
A theoretical study of the binding of polychlorinated biphenyls (PCBs), dibenzodioxins, and dibenzofuran to human plasma prealbumin.
AID161427Relative binding affinity to prealbumin was determined from the competition binding assays and is expressed relative to L-T41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Structurally specific binding of halogenated biphenyls to thyroxine transport protein.
AID161428Concentration at which 50% total binding against prealbumin protein occurs1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Structurally specific binding of halogenated biphenyls to thyroxine transport protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's2 (25.00)18.2507
2000's4 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (1)

ArticleYear
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]